| Literature DB >> 30282927 |
Ana Bettencourt1, Marián Castro2, João Silva3, Francisco Fernandes4, Olga Coutinho5, M João Sousa6, M Fernanda Proença7, Filipe Areias8,9,10.
Abstract
A selection of 1-amino-2-arylidenamine-1,2-(dicyano)ethenes 3 was synthesized and cyclized toEntities:
Keywords: Imidazoles; MIC; antifungal activity; antioxidant capacity; phenolic compounds; structure-activity relationship
Mesh:
Substances:
Year: 2018 PMID: 30282927 PMCID: PMC6222605 DOI: 10.3390/molecules23102530
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Experimental conditions for the synthesis of target compounds 3 and 4.
| Compound | R1 | R2 | R3 | R4 | Reaction Conditions | Yield (%) |
|---|---|---|---|---|---|---|
|
| OH | H | H | H | 97 | |
|
| H | OH | H | H | 82 | |
|
| H | H | OH | H | 87 | |
|
| H | OH | OH | H | 81 | |
|
| H | OH | OH | OH | 92 | |
|
| OH | H | H | H | 50 | |
|
| H | OH | H | H | 70 | |
|
| H | H | OH | H | 63 | |
|
| H | OH | OH | H | 55 |
r.t. (room temperature).
Data from cyclic voltammetry, DPPH● and deoxyribose degradation assays for the target compounds.
| Compound | Ep (mV vs. ECS) | Ep/2 (mV vs. ECS) | DPPH IC50 (μM) | % Inhibition of deoxyribose degradation |
|---|---|---|---|---|
|
| 688 | 649 | n.d. | n.d. |
|
| 740 | - | n.d. | n.d. |
|
| 476 | 361 | n.d. | n.d. |
|
| 248 | 185 | n.d. | n.d. |
|
| 113 | 40 | 3.7 ± 0.7 | 62.1 ± 2.3 |
|
| 783 | 758 | n.d. | n.d. |
|
| 896 | 712 | n.d. | n.d. |
|
| 620 | 534 | n.d. | n.d. |
|
| 254 | 166 | 12.0 ± 1.0 | 59.0 ± 3.5 |
|
| 173 | 107 | 9.0 ± 0.2 | 23.4 ± 2.6 |
Ep (Anodic peak potential); Ep/2 (half peak potential); SCE (saturated calomel electrode); DPPH● (2,2-diphenyl-1-picrylhydrazile radical); IC50 (50% inhibitory concentration); n.d. (not determined).
Values of minimum inhibitory concentration (MIC) on yeast and the viability of fibroblasts at the indicated concentrations of the compounds.
| Compound | Antifungal Activity MIC (μM) | Cellular Viability (%) | |
|---|---|---|---|
|
|
| Fibroblasts | |
|
| >200.0 * | >200.0 * | n.d. |
|
| >200.0 * | >200.0 * | n.d. |
|
| >400.0 * | >400.0 * | n.d. |
|
| >400.0* | >400.0 * | n.d. |
|
|
|
|
|
|
| >400.0 * | >400.0 * | n.d. |
|
| >400.0 * | >400.0 * | n.d. |
|
| >400.0 * | >400.0 * | n.d. |
|
|
|
|
|
|
|
|
| n.d. |
|
|
|
| n.d. |
n.d. (not determined). * Not achieved at highest concentration tested.